Originally posted here: Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain
Originally posted here: Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain
Read the original: Avadel Pharmaceuticals Appoints Sev Melkonian as Vice President of Patient Services, Distribution, and Reimbursement
See the rest here: Spectral AI Provides Update to Investors
Go here to read the rest: Scorpius Holdings Announces Collaboration with KaloCyte to Advance Manufacturing for ErythroMerâ„¢
Here is the original post: Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer
Go here to see the original: Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment
The rest is here: AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
Original post: Sonnet BioTherapeutics to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
Go here to see the original: NeuroSigma Announces Patent Application Protecting Use of Trigeminal Nerve Stimulation to Include Treatment of Dyslexia and Other Neurodevelopmental...
Read more: Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies
Recent Comments